Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 7, 2025
Immunotherapy,
especially
immune
checkpoint
inhibitor
(ICI)
therapy,
has
yielded
remarkable
outcomes
for
some
patients
with
solid
cancers,
but
others
do
not
respond
to
these
treatments.
Recent
research
identified
the
gut
microbiota
as
a
key
modulator
of
responses,
suggesting
that
its
composition
is
closely
linked
responses
ICI
therapy
in
cancer
treatment.
As
result,
microbiome
gaining
attention
potential
biomarker
predicting
individual
and
target
enhancing
treatment
efficacy.
In
this
review,
we
discuss
findings
from
human
observational
studies
assessing
effect
antibiotic
use
prior
on
identifying
specific
bacteria
associated
favorable
unfavorable
responses.
Moreover,
review
investigating
possibility
patient
outcome
prediction
using
machine
learning
models
based
data
before
starting
clinical
trials
exploring
whether
modulation,
example
via
fecal
transplantation
or
live
biotherapeutic
products,
can
improve
results
cancer.
We
also
briefly
mechanisms
through
which
microbial-derived
products
influence
immunotherapy
effectiveness.
Further
necessary
fully
understand
complex
interactions
between
host,
microbiota,
develop
personalized
strategies
optimize
therapy.
Journal of Hematology & Oncology,
Journal Year:
2024,
Volume and Issue:
17(1)
Published: Aug. 9, 2024
The
past
few
decades
have
witnessed
the
rise
of
immunotherapy
for
Gastrointestinal
(GI)
tract
cancers.
role
immune
checkpoint
inhibitors
(ICIs),
particularly
programmed
death
protein
1
(PD-1)
and
PD
ligand-1
antibodies,
has
become
increasingly
pivotal
in
treatment
advanced
perioperative
GI
Currently,
anti-PD-1
plus
chemotherapy
is
considered
as
first-line
regimen
unselected
gastric/gastroesophageal
junction
adenocarcinoma
(G/GEJC),
mismatch
repair
deficient
(dMMR)/microsatellite
instability-high
(MSI-H)
colorectal
cancer
(CRC),
esophageal
(EC).
In
addition,
encouraging
performance
claudin18.2-redirected
chimeric
antigen
receptor
T-cell
(CAR-T)
therapy
later-line
cancers
brings
new
hope
cell
solid
tumour
treatment.
Nevertheless,
remains
yet
precise,
researchers
are
dedicated
to
further
maximising
optimising
efficacy.
This
review
summarises
important
research,
latest
progress,
future
directions
including
EC,
G/GEJC,
CRC.
Biomarker Research,
Journal Year:
2024,
Volume and Issue:
12(1)
Published: Sept. 27, 2024
Abstract
Cells,
as
the
fundamental
units
of
life,
contain
multidimensional
spatiotemporal
information.
Single-cell
RNA
sequencing
(scRNA-seq)
is
revolutionizing
biomedical
science
by
analyzing
cellular
state
and
intercellular
heterogeneity.
Undoubtedly,
single-cell
transcriptomics
has
emerged
one
most
vibrant
research
fields
today.
With
optimization
innovation
technologies,
intricate
details
concealed
within
cells
are
gradually
unveiled.
The
combination
scRNA-seq
other
multi-omics
at
forefront
field.
This
involves
simultaneously
measuring
various
omics
data
individual
cells,
expanding
our
understanding
across
a
broader
spectrum
dimensions.
precisely
captures
aspects
transcriptomes,
immune
repertoire,
spatial
information,
temporal
epitopes,
in
diverse
contexts.
In
addition
to
depicting
cell
atlas
normal
or
diseased
tissues,
it
also
provides
cornerstone
for
studying
differentiation
development
patterns,
disease
heterogeneity,
drug
resistance
mechanisms,
treatment
strategies.
Herein,
we
review
traditional
technologies
outline
latest
advancements
multi-omics.
We
summarize
current
status
challenges
applying
biological
clinical
applications.
Finally,
discuss
limitations
potential
strategies
address
them.
Journal of Hematology & Oncology,
Journal Year:
2025,
Volume and Issue:
18(1)
Published: Jan. 13, 2025
The
tumor
microenvironment
(TME)
is
integral
to
cancer
progression,
impacting
metastasis
and
treatment
response.
It
consists
of
diverse
cell
types,
extracellular
matrix
components,
signaling
molecules
that
interact
promote
growth
therapeutic
resistance.
Elucidating
the
intricate
interactions
between
cells
TME
crucial
in
understanding
progression
challenges.
A
critical
process
induced
by
epithelial-mesenchymal
transition
(EMT),
wherein
epithelial
acquire
mesenchymal
traits,
which
enhance
their
motility
invasiveness
progression.
By
targeting
various
components
TME,
novel
investigational
strategies
aim
disrupt
TME's
contribution
EMT,
thereby
improving
efficacy,
addressing
resistance,
offering
a
nuanced
approach
therapy.
This
review
scrutinizes
key
players
emphasizing
avenues
therapeutically
components.
Moreover,
article
discusses
implications
for
resistance
mechanisms
highlights
current
toward
modulation
along
with
potential
caveats.
Abstract
Recent
advances
in
understanding
the
modulatory
functions
of
gut
and
microbiota
on
human
diseases
facilitated
our
focused
attention
contribution
to
pathophysiological
alterations
many
extraintestinal
organs,
including
liver,
heart,
brain,
lungs,
kidneys,
bone,
skin,
reproductive,
endocrine
systems.
In
this
review,
we
applied
“gut–X
axis”
concept
describe
linkages
between
other
organs
discussed
latest
findings
related
axis,”
underlying
mechanisms
potential
clinical
intervention
strategies.
Gut Microbes,
Journal Year:
2024,
Volume and Issue:
16(1)
Published: Oct. 1, 2024
The
gut
microbiota
can
produce
a
variety
of
microbial-derived
metabolites
to
influence
tumor
development.
Tryptophan,
an
essential
amino
acid
in
the
human
body,
be
converted
by
microorganisms
via
indole
pathway
such
as
Indole-3-Lactic
Acid
(ILA),
Indole-3-Propionic
(IPA),
Indole
Acetic
(IAA)
and
Indole-3-Aldehyde
(IAld).
Recent
studies
have
shown
that
play
key
roles
progression,
they
used
adjuvant
regimens
for
immunotherapy
or
chemotherapy.
Here,
we
summarize
recent
findings
on
common
microbial
provide
review
mechanisms
different
microenvironment.
We
further
discuss
limitations
current
metabolite
research
future
possibilities.
It
is
expected
will
new
strategies
clinical
therapy.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(5), P. 604 - 604
Published: May 8, 2024
The
involvement
of
the
gut
microbiota
in
anti-cancer
treatment
has
gained
increasing
attention.
Alterations
to
structure
and
function
bacteria
are
important
factors
development
cancer
as
well
efficacy
chemotherapy.
Recent
studies
have
confirmed
that
related
metabolites
influence
pharmacological
activity
chemotherapeutic
agents
through
interactions
with
immune
system.
This
review
aims
summarize
current
knowledge
how
malignant
tumor
chemotherapy
affect
microbiota,
regulates
host
response,
between
response
advances
strategies
for
efficiency
based
on
also
described.
Deciphering
complex
homeostasis
maintained
by
immunity
provides
a
solid
scientific
basis
bacterial
intervention
Frontiers in Cellular and Infection Microbiology,
Journal Year:
2025,
Volume and Issue:
14
Published: Jan. 9, 2025
The
microbiome-gut-testis
axis
has
emerged
as
a
significant
area
of
interest
in
understanding
testicular
cancer,
particularly
germ
cell
tumors
(TGCTs),
which
represent
the
most
common
malignancy
young
men.
interplay
between
gut
and
microbiomes
is
hypothesized
to
influence
tumorigenesis
reproductive
health,
underscoring
complex
role
microbial
ecosystems
disease
pathology.
encompasses
interactions
microbiome,
systemic
immune
modulation,
local
microenvironment
testis.
Dysbiosis
or
may
contribute
altered
responses,
inflammation,
hormonal
imbalances,
potentially
playing
pathogenesis
TGCTs.
Concurrently,
seminal
have
been
linked
variations
sperm
quality,
fertility
potential,
possibly
cancer
susceptibility,
need
for
further
evaluation.
This
review
explores
emerging
context
highlighting
its
implications
onset,
progression,
treatment
efficacy,
toxicity.
Identifying
potential
biomarkers,
followed
by
microbiota
modulation
restore
balanced
community,
might
offer
novel
supportive
strategy
improving
efficacy
refractory
TGCT
patients
while
reducing
chemotherapy-induced
We
suggest
better
association
dysregulated
environments
TGCTs
emphasizes
pathways
microbiome
cancer.
